RBM 011
Alternative Names: RBM-011Latest Information Update: 28 Sep 2024
At a glance
- Originator Ribomic
- Class Antihypertensives; Nucleotide aptamers
- Mechanism of Action Interleukin 21 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in Japan
- 25 Aug 2020 Preclinical trials in Pulmonary arterial hypertension in Japan (unspecified route) (Ribomic pipeline, August 2020)
- 01 Jul 2020 Ribomic completes patent application for RBM 011